CMA accuses Canadian firm of overcharging by £100m on thyroid drug with price per pack rising from £4.46 to £258 in 10 yearsConcordia International, the Canadian drug company, has overcharged the NHS by more than £100m in the past decade for a life-changing thyroid drug, according to Britain’s competition watchdog. The regulator said the NHS had spent more than £34m on the drug last year, up from about £600,000 in 2006. This summer, the UK firm Morningside Healthcare and Israel’s Teva were granted licences to supply the drug. Concordia said it would review the findings, but added: “We do not believe that competition law has been infringed. The CMA is carrying out seven other investigations in relation to drug pricing and competition issues.

Source: The Guardian November 21, 2017 08:44 UTC